{
    "Trade/Device Name(s)": [
        "QNext",
        "DG-PT"
    ],
    "Submitter Information": "Diagnostic Grifols S.A.",
    "510(k) Number": "K183390",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160276",
        "K060931"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JPA",
        "GJS"
    ],
    "Summary Letter Date": "July 20, 2019",
    "Summary Letter Received Date": "July 22, 2019",
    "Submission Date": "June 13, 2019",
    "Regulation Number(s)": [
        "21 CFR 864.5425",
        "21 CFR 864.7750"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies",
        "Prothrombin time test, coagulation"
    ],
    "Analyte Class(es)": [
        "coagulation"
    ],
    "Analyte(s)": [
        "Prothrombin Time",
        "International Normalized Ratio (INR)"
    ],
    "Specimen Type(s)": [
        "Human plasma"
    ],
    "Specimen Container(s)": [
        "3.2% sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "QNext"
    ],
    "Method(s)/Technology(ies)": [
        "Optical density detection",
        "Photometric clotting test"
    ],
    "Methodologies": [
        "Clotting test"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Diagnostic Grifols QNext analyzer and DG-PT thromboplastin reagent for automated coagulation (PT/INR) testing on citrated plasma",
    "Indications for Use Summary": "QNext is intended for in vitro diagnostic use in clinical laboratories to perform hemostasis testing by detecting changes in optical density; DG-PT is a reagent for quantitative determination of Prothrombin Time (PT) and monitoring oral anticoagulant therapy with warfarin (INR) in citrated plasma, for use with QNext.",
    "fda_folder": "Hematology"
}